Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.
Stocks · News reference
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on
Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on